Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Expanded access: van toegangsweg tot medicijnen naar bron van onderzoeksdata
dec 2023 | Benigne hematologie, Leukemie, Lymfoom, MDS, MM, MPN, Stamceltransplantatie